Related Experiment Video
Updated: May 8, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic
Zhongju Lu1, Ya-Ping Jiang, Chia-Yen C Wu
1Department of Physiology and Biophysics and the Institute for Molecular Cardiology, Stony Brook University, Stony Brook, New York.
Insights
Diabetes increases the risk of sudden cardiac death by prolonging the QT interval due to reduced phosphoinositide 3-kinase (PI3K) signaling, which elevates the persistent sodium current (INaP). This mechanism explains increased arrhythmias in diabetic patients.
Area of Science:
- Cardiology
- Diabetology
- Molecular Biology
Background:
- Diabetes is a significant risk factor for sudden cardiac death and arrhythmias.
- QT interval prolongation, a marker for arrhythmias, is more prevalent in diabetic patients.
- The underlying mechanisms linking diabetes to QT prolongation are not well understood.
Purpose of the Study:
- To investigate the role of phosphoinositide 3-kinase (PI3K) signaling in diabetes-induced QT interval prolongation.
- To elucidate the specific ion channel alterations contributing to this complication.
Main Methods:
- Studied cardiac myocytes from type 1 and type 2 diabetic mouse models.
- Manipulated PI3K signaling pathways and measured action potential duration (APD) and ion currents.
- Administered insulin, PI3K inhibitors, and INaP blockers to assess their effects on QT interval.
Main Results:
- Diabetic myocytes showed increased APD and persistent sodium current (INaP), which were normalized by PI3K activation.
- QT interval prolongation in diabetic mice was reversed by PI3K activation or INaP blockade.
- Insulin treatment shortened the QT interval in type 1 diabetic hearts, an effect blocked by a PI3K inhibitor.
Conclusions:
- Downregulation of cardiac PI3K signaling in diabetes leads to QT interval prolongation, partly via increased INaP.
- This PI3K-INaP pathway is a key mechanism underlying increased arrhythmia risk in diabetic patients.
- Targeting PI3K signaling or INaP may offer therapeutic strategies for diabetic cardiovascular complications.
Abstract:
Diabetes is an independent risk factor for sudden cardiac death and ventricular arrhythmia complications of acute coronary syndrome. Prolongation of the QT interval on the electrocardiogram is also a risk factor for arrhythmias and sudden death, and the increased prevalence of QT prolongation is an independent risk factor for cardiovascular death in diabetic patients. The pathophysiological mechanisms responsible for this lethal complication are poorly understood. Diabetes is associated with a reduction in phosphoinositide 3-kinase (PI3K) signaling, which regulates the action potential duration (APD) of individual myocytes and thus the QT interval by altering multiple ion currents, including the persistent sodium current INaP. Here, we report a mechanism for diabetes-induced QT prolongation that involves an increase in INaP caused by defective PI3K signaling. Cardiac myocytes of mice with type 1 or type 2 diabetes exhibited an increase in APD that was reversed by expression of constitutively active PI3K or intracellular infusion of phosphatidylinositol 3,4,5-trisphosphate (PIP3), the second messenger produced by PI3K. The diabetic myocytes also showed an increase in INaP that was reversed by activated PI3K or PIP3. The increases in APD and INaP in myocytes translated into QT interval prolongation for both types of diabetic mice. The long QT interval of type 1 diabetic hearts was shortened by insulin treatment ex vivo, and this effect was blocked by a PI3K inhibitor. Treatment of both types of diabetic mouse hearts with an INaP blocker also shortened the QT interval. These results indicate that downregulation of cardiac PI3K signaling in diabetes prolongs the QT interval at least in part by causing an increase in INaP. This mechanism may explain why the diabetic population has an increased risk of life-threatening arrhythmias.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Diabetic Neuropathy
Diabetic Nephropathy
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Type II Diabetes II: Pathophysiology
